Shall We Dance: Evolving Partnerships of Targeted Therapies for AML.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Two publications detailing the clinical outcomes of patients with acute myeloid leukemia and mutations in IDH1, IDH2, or FLT3 who received initial therapy with venetoclax and azacitidine provide new insights into risk stratification and set the stage for future trials integrating molecularly targeted therapy with this new standard regimen. See related articles by Konopleva et al., p. 2744 and Pollyea et al., p. 2753.

Keyphrases

acute myeloid leukemia
low grade
allogeneic hematopoietic stem cell transplantation
wild type
current status
high grade
global health
public health
cell therapy
drug induced
chemotherapy induced